Evidence map›Paper›PMID 38780802›Full record

ArticleAnnals of hematology2024

Acute myeloid leukemia with paraneoplastic pemphigus successfully treated with a personalized antileukemic and immunosuppressive strategy.

Francesca Romana Iovene, Enrico Santinelli, Daniele Armiento, Chiara Sarlo, Chiara Bancone, Lorena Silvestri, Sabrina Erculei, Maria Grazia Sanhust, Antonio Cristiano, Emiliano Fabiani and 5 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Francesca Romana IoveneFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Roma, 200 - 00128, Italy. francesca.iovene@unicampus.it.
Enrico SantinelliFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Roma, 200 - 00128, Italy.
Daniele ArmientoFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Roma, 200 - 00128, Italy.
Chiara SarloFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Roma, 200 - 00128, Italy.
Chiara BanconeFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Roma, 200 - 00128, Italy.
Lorena SilvestriIRCC-IDI Istituto Dermopatico dell'Immacolata, Roma, Italy.
Sabrina ErculeiIRCC-IDI Istituto Dermopatico dell'Immacolata, Roma, Italy.
Maria Grazia SanhustIRCC-IDI Istituto Dermopatico dell'Immacolata, Roma, Italy.
Antonio CristianoFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Roma, 200 - 00128, Italy.
Emiliano FabianiDepartment of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
Mariadomenica DivonaDepartment of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
Camilla PageDepartment of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
Giovanni Di ZenzoIRCC-IDI Istituto Dermopatico dell'Immacolata, Roma, Italy.
Maria CantonettiIRCC-IDI Istituto Dermopatico dell'Immacolata, Roma, Italy.
Luigi RigacciFondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, Roma, 200 - 00128, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bullous pemphigoid (BP) is a rare blistering disease often considered a primary sign of a paraneoplastic syndrome. Retrospective studies have established its link with hematological malignancies, particularly lymphoproliferative disorders. Here, we present what we believe to be the inaugural case of successful simultaneous management of BP and de novo acute myeloid leukemia (AML) in a 28-year-old male patient. Given the rarity and severity of both conditions, our treatment strategy aimed to maximize efficacy by combining immunosuppressive therapy (initially plasmapheresis with high-dose corticosteroids, followed by anti-CD20 monoclonal antibody and intravenous immunoglobulins 2 g/m

Indexed as

Leukemia, Myeloid, AcuteParaneoplastic SyndromesAdultAntineoplastic Combined Chemotherapy ProtocolsCytarabineHumansImmunoglobulins, IntravenousImmunosuppressive AgentsMalePemphigoid, BullousPemphigusPlasmapheresisPrecision MedicineVidarabineCytarabinefludarabineImmunoglobulins, IntravenousImmunosuppressive AgentsVidarabineAcute Myeloid LeukemiaAutologous stem cell transplantationBullous pemphigoidComplete remission

Identifiers

PMID38780802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.